Full-Time

Director – Regulatory Affairs CMC

Confirmed live in the last 24 hours

Pliant Therapeutics

Pliant Therapeutics

51-200 employees

Develops treatments for fibrotic diseases

Biotechnology
Healthcare

Compensation Overview

$230k - $240kAnnually

Senior, Expert

San Bruno, CA, USA

Hybrid position requiring 3 days/week at Pliant in South San Francisco.

Category
Risk & Compliance
Legal & Compliance
Requirements
  • Bachelor’s degree in a scientific discipline required, advanced degree preferred
  • Minimum of 12 years’ experience with 6-10 years in regulatory affairs CMC experience with global clinical phase submissions and health authority interactions
  • Small molecule development or manufacturing experience required, biological experience preferred
  • Experience and knowledge in preparation of initial INDs/IMPD and amendments
  • Experience in health authority interactions and addressing health authority questions
  • Deep knowledge of FDA, EMA and ICH regulatory guidances and regulations
  • Small company / pre-commercial stage company experience desirable
  • Excellent collaboration and cross-functional team participation skills
  • Ability to prioritize and manage multiple tasks while delivering on respective timelines for each
  • Confidence in interacting with varying levels of internal management and external regulatory authorities
  • Preference for applying a solutions-oriented mindset and approach to resolving complex regulatory issues
  • High self-awareness and commitment to iterative learning and development
  • Effective communicator, verbal and written, strong interpersonal and influencing skills
  • Accuracy and attention to details
Responsibilities
  • Develop CMC regulatory strategies in collaboration with regulatory and CMC SMEs to meet business objectives for all Pliant’s development projects, registration, NDA-readiness, and commercial launch
  • Lead the authoring and timely submission of regulatory dossiers as required to support global clinical trial applications, including initial INDs/IND amendments, IMPDs, annual reports, requests for information, etc.
  • Support interactions with global regulatory authorities to ensure acceptance of CMC information in support of regulatory submissions and applications, including leading the authoring of CMC content in briefing documents.
  • Ensure that CMC content in regulatory applications is complete, well-written, and meets all relevant requirements
  • Evaluate proposed manufacturing changes for global impact to ongoing and existing applications and provides strategic regulatory guidance for optimal implementation of changes
  • Participate on project teams and provide expertise on CMC regulatory matters.
  • Knowledge of current and emerging CMC regulatory requirements, guidelines, and best practices, and interpret and communicate relevant issues to CMC and RA colleagues
  • Ensure product labeling is in compliance with regulatory requirements in all regions
  • Assure compliance with regulatory standards and guidance documents
  • Conduct regulatory risk assessments on issues that arise in development teams
  • May lead or support the generation or revision of SOPs related to regulatory affairs and inter-facing Quality workstreams.
  • Work with external regulatory consultants/CRO’s as required.

Pliant Therapeutics develops treatments for fibrotic diseases, which cause thickening and scarring of connective tissue, leading to organ dysfunction. Their products work by targeting the biological mechanisms behind fibrosis, particularly through the inhibition of integrins, proteins that help cells stick together and communicate. This focus allows Pliant to create specific and effective therapies for various fibrotic conditions. Unlike many competitors, Pliant emphasizes a deep understanding of fibrosis and integrin biology, which informs their drug development process. The company's goal is to stop the progression of fibrotic diseases and restore normal organ function, ultimately improving the lives of patients affected by these conditions.

Company Stage

IPO

Total Funding

$201.4M

Headquarters

San Francisco, California

Founded

2015

Growth & Insights
Headcount

6 month growth

6%

1 year growth

12%

2 year growth

49%
Simplify Jobs

Simplify's Take

What believers are saying

  • Pliant's accelerated development of bexotegrast for IPF and positive Phase 2a trial results indicate strong potential for successful market entry.
  • The company's participation in high-profile investor events and scientific congresses enhances its visibility and credibility in the biotech community.
  • Recent strategic appointments, including a new Chief Development Officer and Chief Regulatory Officer, bolster Pliant's leadership team and operational capabilities.

What critics are saying

  • The high costs and long timelines associated with drug development pose financial risks, especially if clinical trials do not meet endpoints.
  • The competitive landscape in biopharmaceuticals, particularly in fibrosis treatment, requires Pliant to continuously innovate to maintain its edge.

What makes Pliant Therapeutics unique

  • Pliant Therapeutics focuses specifically on fibrotic diseases, leveraging deep expertise in fibrosis and integrin biology, unlike competitors with broader therapeutic areas.
  • Their targeted approach to integrin inhibition offers a unique mechanism of action that sets them apart from other fibrosis treatments.
  • Pliant's commitment to rigorous clinical trials and data-driven development ensures high standards of efficacy and safety, distinguishing them in the biopharmaceutical market.

Help us improve and share your feedback! Did you find this helpful?